skip to main content
Idioma:
previous page 1 Resultados 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Oxford University Press:Jisc Collections:Medicine Collection:2018 remover idioma: Inglês remover
Result Number Material Type Add to My Shelf Action Record Details and Options
11
DOP66 INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulas
DOP66 INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulas
Material Type:
Artigo 		Adicionar ao Meu Espaço

DOP66 INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulas

Fathallah, N ; Zmora, O ; Baumgart, D C ; Faubion, W ; Ferrante, M ; Gecse, K ; Wright, E ; McKay, C ; Ren, K ; Punchard, M ; Zhang, B ; Panés, J

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i192-i194 [Periódico revisado por pares]

UK: Oxford University Press

Texto completo disponível

Citações Citado por
12
P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

Vermeire, S ; Peyrin-Biroulet, L ; Panés, J ; Regueiro, M ; Kotze, P G ; Charabaty, A ; Goetsch, M ; Shan, K ; Wu, J ; McDonnell, A ; Woolcott, J ; Danese, S

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i619-i620 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
13
P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

Panés, J ; Loftus Jr, E V ; Armuzzi, A ; Siegmund, B ; Sands, B E ; Boland, B S ; Kalabic, J ; Lai, J H ; Sharma, D ; Remple, V ; Sanchez Gonzalez, Y ; Lindsay, J O

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1596-i1597 [Periódico revisado por pares]

UK: Oxford University Press

Texto completo disponível

Citações Citado por
14
P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease
P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease
Material Type:
Artigo 		Adicionar ao Meu Espaço

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

Panés, J ; Louis, E ; Bossuyt, P ; Joshi, N ; Lee, W J ; Lacerda, A ; Remple, V ; Xuan, S ; Loftus Jr, E V

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i919-i920 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
15
P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease
P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease
Material Type:
Artigo 		Adicionar ao Meu Espaço

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

Panés, J ; Louis, E ; Bossuyt, P ; Joshi, N ; Lee, W J ; Lacerda, A ; Remple, V ; Xuan, S ; Loftus Jr, E V

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i568-i569 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
16
DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease
DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease
Material Type:
Artigo 		Adicionar ao Meu Espaço

DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease

Gudiño, V ; Cho, J W ; Corraliza, A M ; Caballol, B ; Garrido-Trigo, A ; Masamunt, M C ; Ordás, I ; Ricart, E ; Hemberg, M ; Panés, J ; Salas, A

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i140-i142 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
17
P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

Armuzzi, A ; Rubin, D T ; Schreiber, S ; Panés, J ; Fellmann, M ; Bartolome, L ; Goetsch, M ; Bhattacharjee, A ; Wu, J ; Chaparro, M ; Dubinsky, M C

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i593-i594 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
18
P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
Material Type:
Artigo 		Adicionar ao Meu Espaço

P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity

Siegmund, B ; Patel, K ; Torres, E A ; Lakatos, P L ; Seidelin, J ; Fleisher, M ; Ford, S ; Remple, V ; Lacerda, A P ; Anyanwu, S ; Garrison, A ; Panés, J

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i636-i637 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
19
P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study
P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study
Material Type:
Artigo 		Adicionar ao Meu Espaço

P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study

Rubin, D T ; Panés, J ; Torres, J ; Kobayashi, T ; Su, C ; Lawendy, N ; Modesto, I ; Segovia, M ; Gardiner, S ; Wang, W ; Vermeire, S

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i914-i916 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
20
P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
Material Type:
Artigo 		Adicionar ao Meu Espaço

P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open

Biedermann, L ; Dubinsky, M C ; Vermeire, S ; Fellmann, M ; Gardiner, S ; Hur, P ; Mundayat, R ; Panés, J ; Rubin, D T

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i317-i319 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
previous page 1 Resultados 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (207)
  2. Revistas revisadas por pares (211)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (210)
  2. Outros  (1)
  3. Anais de Congresso  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2006  (5)
  2. 2006Até2009  (21)
  3. 2010Até2013  (20)
  4. 2014Até2018  (63)
  5. Após 2018  (104)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.